New GLP-1 Agonists Show Promise in Reducing Cravings and Substance Abuse

Recent studies highlight the potential of GLP-1 agonists, such as Ozempic and Wegovy, in addressing both weight management and substance abuse disorders. Originally developed to treat type 2 diabetes by mimicking the GLP-1 hormone to manage blood sugar, these medications have shown unexpected side effects, including significant weight loss and reduced alcohol consumption.

Research dating back to the 1970s has established a link between vivid mental imagery and substance abuse, underscoring the importance of understanding the craving-consumption connection in addiction. Preclinical animal studies suggest that GLP-1 agonists may also lower usage of other addictive substances, including cocaine, amphetamines, opiates, and nicotine.

Understanding the Brain’s Reward System

Traditionally, the brain’s reward circuitry has been studied through regions like the ventral tegmental area (VTA) and nucleus accumbens (NAc), which are associated with dopamine production. Despite their relevance, these areas lack significant GLP-1 receptor density and may not account for the drugs’ mechanisms. Instead, researchers are now focusing on the lateral septum, a structure linked to emotional regulation.

Named during the 1950s by researchers Joseph Brady and Walle Nauta, “septal rage” describes increased aggression in animals with lateral septum damage. Current research places the lateral septum as central within a neural connectivity network, revealing its complex role beyond aggression.

The lateral septum receives input from the hippocampus, a region crucial for forming long-term memories. It has been recently demonstrated that both the hippocampus and lateral septum contain “place cells” that not only identify spatial and temporal contexts but also respond to rewards, effectively integrating location and value information before relaying it to the dopamine-producing areas.

The Role of GLP-1 Receptors

Rich in GLP-1 receptors, the lateral septum may serve as a critical mechanism for the anti-consumption effects of GLP-1 agonists. Studies have indicated that GLP-1 activation in this region can reduce food intake in mice, and recent findings suggest similar effects on alcohol consumption. Moreover, research from this year shows that GLP-1 drugs can lower specific activity in the lateral septum, potentially affecting its communication with other brain regions.

These insights are redefining our understanding of how the brain processes rewards and may pave the way for new treatment strategies for both obesity and substance dependence.